Short Interest in Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) Increases By 40.5%

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) saw a significant growth in short interest in the month of October. As of October 31st, there was short interest totalling 7,670,000 shares, a growth of 40.5% from the October 15th total of 5,460,000 shares. Approximately 5.6% of the shares of the company are short sold. Based on an average daily volume of 31,930,000 shares, the short-interest ratio is presently 0.2 days.

Institutional Trading of Tonix Pharmaceuticals

A hedge fund recently raised its stake in Tonix Pharmaceuticals stock. Acadian Asset Management LLC lifted its holdings in Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) by 260.6% in the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 335,373 shares of the company’s stock after purchasing an additional 242,358 shares during the quarter. Acadian Asset Management LLC owned 0.40% of Tonix Pharmaceuticals worth $61,000 at the end of the most recent quarter. 82.26% of the stock is currently owned by hedge funds and other institutional investors.

Tonix Pharmaceuticals Stock Down 6.4 %

Shares of NASDAQ TNXP traded down $0.01 during trading hours on Friday, hitting $0.13. The company had a trading volume of 10,509,191 shares, compared to its average volume of 10,158,421. The company has a quick ratio of 0.72, a current ratio of 1.15 and a debt-to-equity ratio of 0.13. Tonix Pharmaceuticals has a 1-year low of $0.12 and a 1-year high of $22.14. The firm’s 50 day moving average is $0.15 and its 200-day moving average is $1.44. The stock has a market capitalization of $17.99 million, a P/E ratio of 0.00 and a beta of 2.06.

Tonix Pharmaceuticals (NASDAQ:TNXP) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.23) EPS for the quarter, topping analysts’ consensus estimates of ($2.03) by $1.80. Tonix Pharmaceuticals had a negative return on equity of 158.64% and a negative net margin of 1,197.86%. The company had revenue of $2.82 million for the quarter, compared to analyst estimates of $2.63 million. On average, analysts expect that Tonix Pharmaceuticals will post -18 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on TNXP shares. StockNews.com assumed coverage on Tonix Pharmaceuticals in a research report on Wednesday. They set a “sell” rating for the company. Alliance Global Partners lifted their target price on Tonix Pharmaceuticals from $6.00 to $11.00 and gave the stock a “buy” rating in a research report on Monday, July 22nd.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.